1. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005;62:975-983.
2. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162:1785-1804.
3. Fusar-Poli P. The Clinical High-Risk State for Psychosis (CHR-P), Version II. Schizophr Bull 2017;43:44-47.
4. Addington J. The prodromal stage of psychotic illness: observation, detection or intervention? J Psychiatry Neurosci 2003;28:93-97.
5. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry 2009;70:1206-1212.
6. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012;69:220-229.
7. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005;39:964-971.
8. Lee TY, Kim SN, Correll CU, Byun MS, Kim E, Jang JH, et al. Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study. Schizophr Res 2014;156:266-271.
10. Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry 2016;73:113-120.
14. Mitter N, Nah GQ, Bong YL, Lee J, Chong SA. Longitudinal Youth-At-Risk Study (LYRIKS): outreach strategies based on a community-engaged framework. Early Interv Psychiatry 2014;8:298-303.
15. Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 2013;43:1133-1149.
18. Wood SJ, Yung AR, McGorry PD, Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the atrisk mental state to chronic schizophrenia. Biol Psychiatry 2011;70:619-625.
20. Addington J, Stowkowy J, Weiser M. Screening tools for clinical high risk for psychosis. Early Interv Psychiatry 2015;9:345-356.
21. Loewy RL, Bearden CE, Johnson JK, Raine A, Cannon TD. The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophr Res 2005;79:117-125.
25. Fonseca-Pedrero E, Gooding DC, Ortuno-Sierra J, Paino M. Assessing self-reported clinical high risk symptoms in community-derived adolescents: a psychometric evaluation of the Prodromal Questionnaire-Brief. Compr Psychiatry 2016;66:201-208.
27. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002;159:863-865.
28. O’Toole BI. Screening for low prevalence disorders. Aust N Z J Psychiatry 2000;34(Suppl):S39-S46.
29. Kobayashi H, Nemoto T, Koshikawa H, Osono Y, Yamazawa R, Murakami M, et al. A self-reported instrument for prodromal symptoms of psychosis: testing the clinical validity of the PRIME Screen-Revised (PS-R) in a Japanese population. Schizophr Res 2008;106:356-362.
31. Chung YC, Kang NI, Im YJ, Kim SW, Cho IH, Lee YM, et al. Validation of the Korean version of the Eppendorf Schizophrenia Inventory as a screening measure to detect adolescents at ultra-high risk for psychosis. Early Interv Psychiatry 2013;7:71-79.
32. Owoso A, Ndetei DM, Mbwayo AW, Mutiso VN, Khasakhala LI, Mamah D. Validation of a modified version of the PRIME screen for psychosis-risk symptoms in a non-clinical Kenyan youth sample. Compr Psychiatry 2014;55:380-387.